2024-05-02 16:00:35 ET
Summary
- Annovis Bio's pipeline features a single therapeutic drug, Buntanetap, unlikely to showcase efficacy in AD or PD.
- Topline data of AD phase II/III trial was released in a press release, and featured a small post-hoc sub-population.
- The stock plummeted 70% on press release announcements.
- Topline data of PD phase III trial was postponed multiple times, with no definitive deadline, despite study completion prior to AD.
Introduction
Annovis Bio ( ANVS ), a clinical-stage biopharmaceutical company, is actively engaged in developing new treatments for neurodegenerative diseases. Its pipeline features a single therapeutic drug in late development stage, buntanetap (ANVS402), a small molecule and an enantiomer of Phenserine, a previously failed AD drug. The pipeline also features ANVS405, which is buntanetap administered intravenously, and ANVS301, a molecule targeting butyrylcholinesterase enzyme . We first discussed Annovis in January 2024, raising concerns about the scientific basis for using the compound and offering predictions on the outcomes of their Alzheimer's disease ((AD)) and Parkinson's disease ((PD)) trials. We suggest that readers review our initial analysis before proceeding with this update. Recently, Annovis has disclosed its latest AD trial results, delayed its PD trial without sufficient explanation, and updated its financial status. We are re-evaluating the company's future prospects....
Read the full article on Seeking Alpha
For further details see:
Annovis Bio: Alzheimer's Disease Topline Data Disappoints The market